Merck will continue DTC for Singulair, Januvia, says CFO

Share this article:

In an analyst call, Merck EVP and CFO Peter Kellogg said the company plans “continued DTC efforts for Singulair and Januvia as well as appropriate promotional support for Gardasil, RotaTeq and Zostavax,” along with support for the launch of Isentress and hopeful Cordaptive.

Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.